8-K: REGENXBIO Reports Positive Financial Results and Operational Progress, BLA Submitted for RGX-121

REGENXBIO announces fourth quarter and full year 2024 financial results, highlighting the BLA submission for clemidsogene lanparvovec (RGX-121) and strategic partnership with Nippon Shinyaku.

Summary

• REGENXBIO reported its fourth quarter and full year 2024 financial results.
• A Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) has been submitted and is on track for potential FDA approval in the second half of 2025.
• A strategic partnership with Nippon Shinyaku aims to expand potential access and commercial opportunity in MPS II and MPS I.
• The pivotal trial of RGX-202 for Duchenne Muscular Dystrophy is progressing rapidly, with enrollment completion expected in 2025 and a BLA filing in mid-2026.
• AbbVie-partnered retinal franchise continues advancing, with pivotal data evaluating the safety and efficacy of surabgene lomparvovec (ABBV-RGX-314) expected in 2026.
• Cash, cash equivalents, and marketable securities were $244.9 million as of December 31, 2024, compared to $314.1 million as of December 31, 2023.
• Revenues were $21.2 million and $83.3 million for the three months and full year ended December 31, 2024, respectively.
• Net loss was $51.2 million for the three months ended December 31, 2024, and $227.1 million for the year ended December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the BLA submission, strategic partnership, and progress in clinical trials. However, the net loss and decrease in cash position temper the overall outlook.

Positives

• The BLA submission for RGX-121 marks a significant step towards potential commercialization.
• The partnership with Nippon Shinyaku provides substantial upfront funding and potential future milestone payments.
• RGX-202 is progressing rapidly through pivotal study and continues to demonstrate a differentiated profile.
• The AbbVie partnership continues to advance multiple large, global commercial opportunities.
• The company's cash runway extends into the second half of 2026.

Negatives

• Cash, cash equivalents and marketable securities decreased from $314.1 million as of December 31, 2023 to $244.9 million as of December 31, 2024.
• Revenues decreased from $90.2 million in 2023 to $83.3 million in 2024.
• The company reported a net loss of $227.1 million for the year ended December 31, 2024.

Risks

• The timing of enrollment, commencement, and completion of clinical trials could impact the company's development timelines.
• The success of clinical trials conducted by REGENXBIO, its licensees, and its partners is uncertain.
• The timing or likelihood of payments from AbbVie or Nippon Shinyaku is not guaranteed.
• The ability to obtain and maintain regulatory approval of product candidates is subject to regulatory review and potential delays.
• The company's financial guidance excludes the impact of any material payments that may potentially be received from partners or licensees upon the achievement of development or regulatory milestones.

Future Outlook

REGENXBIO expects its cash balance and the $110 million upfront payment from Nippon Shinyaku to fund operations into the second half of 2026. The company anticipates potential FDA approval of RGX-121 in the second half of 2025 and a BLA filing for RGX-202 in mid-2026.

Management Comments

• In 2025, we have already submitted our first BLA and will accelerate late-stage development and advance commercial preparations for multiple potential product launches, said Curran M. Simpson, President and Chief Executive Officer of REGENXBIO.
• RGX-202 is progressing rapidly through pivotal study, continues to demonstrate a differentiated profile, and remains on track to be the next gene therapy in Duchenne.

Industry Context

REGENXBIO is operating in the competitive gene therapy space, focusing on rare and retinal diseases. The company's progress with RGX-121, RGX-202, and ABBV-RGX-314 positions it to potentially compete with existing treatments and other gene therapy developers in these areas. The partnerships with Nippon Shinyaku and AbbVie are strategic moves to expand market access and accelerate development.

Comparison to Industry Standards

• REGENXBIO's reliance on Zolgensma royalties highlights the importance of successful commercial partnerships in the gene therapy space, similar to how companies like Sarepta Therapeutics depend on their Duchenne Muscular Dystrophy franchise.
• The $110 million upfront payment from Nippon Shinyaku is comparable to other licensing deals in the gene therapy sector, such as those seen with companies like BioMarin and Ultragenyx.
• The projected cash runway into the second half of 2026 is a key metric for investors, as it provides visibility into the company's ability to fund its ongoing clinical trials and development programs, similar to how investors assess cash runway for companies like CRISPR Therapeutics and Editas Medicine.

Management Changes

Stakeholder Impact

• Shareholders may be positively impacted by the potential approval of RGX-121 and the progress of other pipeline candidates.
• Patients with MPS II, Duchenne Muscular Dystrophy, wet AMD, and diabetic retinopathy could benefit from the development of new gene therapies.
• Employees may benefit from the company's growth and success.
• The partnership with Nippon Shinyaku could expand market access and commercial opportunities.

Next Steps

• REGENXBIO will continue to advance the clinical development of RGX-202, ABBV-RGX-314, and other pipeline candidates.
• The company will work with the FDA to secure approval for RGX-121.
• REGENXBIO will collaborate with Nippon Shinyaku to develop and commercialize RGX-121 and RGX-111.
• The company will continue to manage its cash resources to fund operations into the second half of 2026.

Key Dates